Home  > News  > Noteworthy


Please find below news in brief from Ascenion, its partners and the technology transfer sector:


Come und join the 8th edition of BioFIT, Europe’s Top Event for Academia-Industry Collaborations in the field of Life Sciences

More than 1,300 delegates from 35+ countries, such as big pharma, emerging and small biotech, diagnostics companies, pre-seed, seed and Series-A investors, as well as professionals from tech transfer, academia and research institutions will come together in December for BioFIT, a partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences.

As a supporter of BioFIT Ascenion cordially invites all its partners to join this partnering event to take place on 10-11 December 2019 in Marseille, France.

Further information:
Learn more!
Agenda 2019


Training course on 24 October 2019 in Munich: CDA, MTA, Term Sheets – everything you need to know about contracts in the run-up to cooperations

Confidential disclosure agreements, material transfer agreements and term sheets – all these contracts have to be closed during the planning phase of a research project. Mistakes made at this stage can seriously compromise the project. This one-day course on the 24 October 2019 will teach you everything you need to know to avoid such mistakes and ensure that research projects are contractually well-positioned from the start. Thieß Matzke and Thomas Schöpke, lawyers at Ascenion, pass on their accumulated knowledge and experience from negotiating hundreds of contracts. You will learn about important basic principles, typical pitfalls and all the dos and don’ts.

The course is offered in cooperation with TransferAllianz, the German association for knowledge and technology transfer (formerly TechnologieAllianz). The continuing education programme initiated by TransferAllianz and its members reflects one of the association’s key goals: to share know-how and experience in knowledge and technology transfer (KTT) and establish a high professional standard for KTT in Germany.

The course will be held in German. 

You can find details of the course programme and how to register here.


HKI and partners receive IQ Innovation Award for novel antibiotic against tuberculosis

This year’s innovation prize from the Metropolregion Mitteldeutschland goes to a team that has brought a novel anti-tuberculosis compound all the way from basic research to clinical studies – largely funded by public grants. The winners are Dr Florian Kloß from the Leibniz Institute for Natural Product Research and Infection Biology – Hans-Knoell-Institute (HKI), Dr Julia Dreisbach from the Ludwig-Maximilians-Universität München (LMU) and Dr Uwe Müller, CEO of HAPILA GmbH.

The antibiotic candidate identified at HKI has a new and unique mode of action with strong potential to combat tuberculosis caused by multidrug-resistant pathogens. Phase I trials have successfully been completed, and a phase II study is currently being prepared.

Ascenion, the HKI’s technology transfer partner, has managed all IP-relevant aspects of the project throughout the years and helped structure all partnership agreements.

Further information:
See HKI’s press release (German)


Don’t miss the BioEntrepreneurship Summit 2019

Be part of Munich’s vibrant bioentrepreneurial ecosystem and join the BioEntrepreneurship Summit on 15 – 16 October 2019.
The event is organized by BioM and brings together key players: students, scientists and entrepreneurs (to be) with experienced managers, industry leaders, life-science investors, business angels and tech transfer specialists. The program combines start-up pitches with inspiring talks and hands-on workshops. In addition, there will be the opportunity to participate in the m4 award ceremony.

Apply now for the Preseed / Startup Pitch.
Application deadline is July 15, 2019.

For program details and registration see the event website


Welcome to the team!

Ascenion welcomes two new colleagues in Munich:

Shahin Panahi supports the controlling team in the field of accounting since February 2019. Trained as an office administrator and qualified accountant she brings many years of experience to the team. In parallel, she is currently completing an IHK training to become a certified management accountant.

Dr Manal Chatila-Schiffer joined Ascenion in April 2019 to support the team in business and technology development. She draws on dedicated expertise with several years of experience in the life-science sector. She was a consultant to the pharma industry, in charge of business development for a life-science start-up and gained experience in IP asset management at Max Planck Innovation. She holds a PhD in biochemistry from the Max Planck Institute for Biochemistry in Martinsried, Munich.


Berlin Cures starts Phase IIa trial in heart failure

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized, open-label trial will evaluate the candidate’s safety and biological efficacy in patients with chronic heart failure. Phase I data demonstrated excellent tolerability, with no clinically relevant side effects.

BC 007, a DNA aptamer, selectively binds and neutralizes autoantibodies against G-protein-coupled receptors that causally contribute to heart failure. If successful it would provide the first causative treatment for millions of patients. Heart failure is one of the leading causes of death in the western world, with a socioeconomic burden that is equivalent to that of cancer.

For further information:
See Berlin Cures’ press release


12th BioVaria on May 8 - 9, 2019 – Don’t miss the opportunity!

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Top-tier academic institutions and universities from all over Europe will present over 60 attractive partnering and investment opportunities in the life-science field.

  • Unparalleled density of highly innovative commercial opportunities
  • 15 technology transfer partners from five European countries
  • 10 life-science startups from Austria, Czech Republic, Denmark, Germany and Norway participating in this year’s Startup Pitch and Partner event
  • Interactive panel discussion on “From stem cells to therapy: Development of cell based approaches in regenerative medicine” moderated by Dr Martin Raditsch, CEO, Innovectis GmbH.

Register here www.biovaria.org.

Further information:

Technologies online



OMEICOS starts Phase II Trial in Atrial Fibrillation

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled, double-blind, randomized PROMISE-AF study will evaluate the efficacy and safety of the candidate in patients with persistent atrial fibrillation (AF). In total, the company expects to enrol up to 120 participants in four European countries.

OMT-28, a synthetic small molecule analogue of a natural omega-3 fatty acid metabolite, targets one of nature’s most important cell-protective pathways. If successful, it would introduce a novel treatment modality in the segment of anti-arrhythmic drugs, with potential benefits for millions of patients.

For further information see OMEICOS’ press release


Charité BIH Entrepreneurship Summit, Berlin, June 17 - 18, 2019

Join over 400 experts in medical innovation to discuss global challenges and pioneering technologies in healthcare. During two conference days, you will get access to entrepreneurs, scientists and clinicians, policymakers, investors, and industry leaders.

The agenda features influential speakers from Germany, Europe, Israel, the United States, and Australia. The keynote topics of 2019 will include AI in healthcare, drug repurposing, investment models, digital therapeutics, and clinical trials. This year has a special focus on the Massachusetts region and therefore has a strong emphasis on transatlantic collaboration.

The Life Sciences Venture Market offers opportunities for entrepreneurs to present their companies to international investors. In addition, the following interactive workshops on relevant strategic issues are offered:

  • Lessons learned from the fundraising trenches: the good, the bad and the ugly
    Charlie Cameron, Cooley LLP Boston, MA and John Hession, Morse Barnes-Brown Pendleton, Waltham, MA
  • Understanding Healthcare and Hospitals – what innovators and founders need to know to success in the world of rules and regulation in Germany. A perspective from consulting experts. Christian Wallwiener and Marina Leonie Moskvina, WMC Healthcare Munich, Germany

Ascenion is partner of the Charité BIH Entrepreneurship Summit 2019. As a member of our network you save up to 33% at registration. Contact us!

Find out more about the Summit and register at: www.charite-summit.de.


Ascenion supports collaboration agreement between HZI / HIPS and GARDP

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with the Global Antibiotic Research and Development Partnership (GARDP) to discover novel antibiotics. Ascenion, the HZI’s technology transfer partner, supported the deal.

The partners will focus on drug-resistant pathogens that are most threatening to public health according to WHO’s classification. HIPS will contribute its unique library of natural compounds to the global drug discovery initiative, which brings together leading institutes and public private partnerships to combat antibacterial resistance. Besides HIPS and GARDP, it embraces the open-access screening initiative CO-ADD and Calibr, the translational division of Scripps Research.

For further information see the HZI's press release


Gramibactin is Leibniz Compound of the Year 2019

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the iron supply of both the microorganisms and their host plants. It captures iron(III) from the environment through N nitroso-hydroxylamine groups that have not been observed in any other natural iron transporter so far. This unique binding motif not only fixes iron with high affinity but also serves as a nitric oxide (NO) donor.

These findings may contribute to improving plant growth and crop yield in a natural way. In plants, iron is essential for chlorophyll production, and NO is involved in several regulatory processes. Gramibactin was discovered by Christian Hertweck and his team at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI).

Due to the strong potential it holds for cereal production, it was named ‘Leibniz Compound of the Year’. The compound is available for licencing or co-development through Ascenion, the HKI’s technology transfer partner.

Further information:


ISAR Bioscience Translational R&D project competition: Call for proposals

ISAR Bioscience is sponsor of BioVaria 2019, Europe’s leading showcasing event for life science technologies. ISAR is committed to translational R&D in the field of applied stem cell and regenerative medicine research. ISAR invites scientists and R&D organizations to submit early-stage or more advanced translational R&D project proposals for recognition, support & funding. All areas of applied biomedical and therapeutic research are welcome but R&D project proposals must encompass ISAR key technologies such as for instance hiPSC and cell differentiation, genome engineering, next generation disease models for therapeutic discovery and regenerative medicine, cell-based models for industrial biotechnology applications, 3D spheroid/organoid tissue models, microfluidics, or laboratory automation. Confidentiality is guaranteed and all proposals will be internally evaluated. Select applicants will be invited to pitch their translational R&D project to the ISAR jury in a confidential ISAR satellite session at BioVaria 2019. The winning ISAR R&D proposal will be announced and honored with € 2,000 at the ISAR award ceremony held at BioVaria 2019 and will be further evaluated whether it is eligible for ISAR support and funding. R&D project proposals must be submitted no later than April 12th 2019.

Further information and application instructions see competition website.


Join ASTP-Proton’s 20th Annual Conference on 21 – 23 May 2019 in Dublin

Get ready for Europe’s largest event for knowledge and technology transfer (KTT): ASTP-Proton’s Annual Conference is taking place in Dublin on 21 – 23 May 2019. The meeting attracts hundreds of KTT professionals from across the world as well as major stakeholders from industry, SMEs, finance and government. Two interactive days offer multiple opportunities for learning and networking. The program includes inspiring key notes from international top speakers, e.g. from Israel and Saudi Arabia, and workshops and panel discussions on hot topics such as artificial intelligence. In addition, participants can arrange for one-on-one meetings with representatives from EU projects, KTT-offices or industry to share experience and identify opportunities for collaboration.

Arrive on 21 May in the morning and join the pre-conference program which includes two free training workshops, a visit to the Guinness Enterprise Centre, and walking tour of Dublin!

For further information on programme and registration please visit the conference website.


EIT Health Accelerator: Dedicated support for Europe’s top entrepreneurs

This is an exciting opportunity for European healthcare entrepreneurs, start-ups and SMEs: EIT Health invites you to apply for participation in the EIT Health Accelerator, a EU-backed programme providing dedicated support at every stage of the business development process, from ideation to scale-up. Supportive actions break down into three key sections: INCUBATE, VALIDATE and SCALE. Choose the programme that best suits your venture’s development stage:

  • INCUBATE targets academics working on ideas in medtech, biotech or digital health. It offers access to dedicated Bootcamp programmes, which are designed to help start-ups develop and validate their business idea, and prepare to launch across the European market.
  • VALIDATE is for start-ups and SMEs that want to test and improve their products. It includes access to test labs, mentoring, funding and training, e.g. in the fields of regulatory and marketing. 
  • SCALE focuses on more mature start-ups and SMEs. It provides access to advanced tools and networks for financing and market expansion.

Don’t miss the opportunity to benefit from the EU’s vibrant start-up ecosystem.

  • Learn more about the EIT Accelerator.
  • If you are located in the DACH region also explore the slack group for start-ups where information about upcoming deadlines and opportunities is published regularly.


Ascenion supports negotiations for licence agreement between HZI and InvivoGen

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence agreement between the institute and InvivoGen, a global provider of life-science research products. Under the terms of the agreement the company obtains the right to commercialise c-di-AMP as a vaccine adjuvant for research projects. The compound is a second messenger in bacteria, where it plays a crucial role in the coordination of growth and the establishment of bacterial infection. HZI researchers have shown that it can boost cellular immune response when co-administered with vaccines via various routes, including mucosal applications. This makes it an attractive adjuvant for all approaches aiming to establish effective immune protection, involving the mucosa as point of entrance.

The compound is available at preclinical grade from InvivoGen at